Medical Management of Parkinson’s Disease: Focus on Neuroprotection by Boll, Marie-Catherine et al.
350 Current  Neuropharmacology, 2011, 9, 350-359
  1570-159X/11 $58.00+.00  ©2011 Bentham Science Publishers Ltd.
Medical Management of Parkinson’s Disease: Focus on Neuroprotection 
Marie-Catherine Boll
1, Mireya Alcaraz-Zubeldia
2 and Camilo Rios
2,*
1Department of Clinical Investigation in Neurology National Institute of Neurology and Neurosurgery, Mexico. D.F.; 
2Department of Neurochemistry National Institute of Neurology and Neurosurgery, Mexico, D.F. 
Abstract: Neuroprotection refers to the protection of neurons from excitotoxicity, oxidative stress and apoptosis as 
principal mechanisms of cell loss in a variety of diseases of the central nervous system. Our interest in Parkinson’s disease 
(PD) treatment is focused on drugs with neuroprotective properties in preclinical experiments and evidence-based efficacy 
in human subjects. To this date, neuroprotection has never been solidly proven in clinical trials but recent adequate mark-
ers and/or strategies to study and promote this important goal are described. A myriad of compounds with protective 
properties in cell cultures and animal models yield to few treatments in clinical practice. At present, markers of neuronal 
vitality, disease modifying effects and long term clinical stability are the elements searched for in clinical trials. This re-
view highlights new strategies to monitor patients with PD. Currently, neuroprotection in subjects has not been solidly 
achieved for selegiline and pramipexole; however, a recent rasagiline trial design is showing new indications of disease 
course modifying effects. In neurological practice, it is of utmost importance to take into account the potential neuropro-
tection exerted by a treatment in conjunction with its symptomatic efficacy. 
Keywords: Parkinson´s disease, neuroprotection, clinical trial, rasagiline, pramipexole. 
1. INTRODUCTION 
  Although multiple neuronal systems are involved, the 
hallmark of Parkinson’s disease (PD) pathology is centered 
on cell loss in substantia nigra pars compacta (SNc) directly 
affecting the dopaminergic nigro-striatal pathway. Strategies 
to monitor dopamine nerve terminals in vivo in PD brains 
include striatal uptake of (18)fluorodopa or (11)C-beta-CFT 
[2-beta-carbomethoxy-3beta-(4-fluorophenyl) tropane] re-
vealed, by positron emission tomography (PET) [1, 2, 3] and 
beta-CIT or (123)I in single-photon emission computerized 
tomography (SPECT), to show distribution of dopamine 
transporters (DAT), among other tracer-DAT ligands [4, 5]. 
However, it has not yet been confirmed that striatal uptake of 
these isotopes does in fact correlate with the remaining num-
ber of dopamine neurons or terminals. Furthermore, the pos-
sibility of a confounding pharmacological effect has not yet 
been completely excluded [6]. Vesicular monoamine trans-
porter-2 (VMAT-2) and Nurr1 are two other surrogate mark-
ers of DA neuron function whose expression is still being 
studied in cell cultures and tissues [7, 8]. Based on the possi-
ble interventions available for protecting vulnerable neurons, 
different strategies and treatment algorithms have been pre-
sented [9, 10]. However, until now, no drug has yet been 
established as a neuroprotective agent in human subjects, and 
none has yet been approved for neuroprotective indication. 
In 2003, twelve potentially neuroprotective compounds were 
prioritized by a large expert group, the CINAPS (NIH-   
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appointed Committee to Identify Neuroprotective Agents in 
Parkinson´s; for consultation, see Table 1), to be further 
studied in clinical trials [11]. We present here the mecha-
nisms studied and the actual status of those compounds,   
as well as new drugs with protective properties that are cur-
rently being used in human subjects. The order of presenta-
tion provided here is based on the chronologic neuroprotec-
tive focus attributed to a compound or class of drug in clini-
cal practice. 
2. COMPOUNDS OR CLASS OF DRUGS PRIORITIZED 
FOR THEIR NEUROPROTECTIVE PROPERTIES 
2.1. MAO-B Inhibitors 
2.1.1. Selegiline  
  Among the drugs that have received most of the attention 
in relation to neuroprotection, selegiline (deprenyl) and 
rasagiline stand out, which are monoamine oxidase type-B 
(MAO-B) inhibitors. Both of these compounds of the prop-
argylamine group have demonstrated neuroprotective effi-
cacy in cell culture and animal models. Selegiline not only 
protects cultured dopaminergic neurons against MPP+ (1-
methyl-4-phenylpyridine), the toxic metabolite of MPTP (1-
methyl-4-phenyl-1, 2,3,6-tetrahydropyridine) [12], but also 
reduces the cell death cascade caused by MPTP in animal 
models [13]. These benefits were initially thought to depend 
only on monoamine oxidase B inhibition through prevention 
of excessive production of reactive oxygen species (ROS) by 
catabolism of monoamines, but it is now known that se-
legiline also enhances the synthesis of neurotrophic factors 
[14]. This compound can also protect against apoptotic cell 
death, possibly via an increased production of Bcl-2, a mem-
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chrome c into the cytoplasm and the resulting destructive 
cascade of compounds [14, 15, 16], or by maintaining   
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a 
dimer, thereby preventing its nuclear translocation and its 
blocking upregulation of anti-apoptotic proteins [13, 14, 17]. 
  The DATATOP (Deprenyl and Tocopherol Antioxidant 
Therapy of PD) study is the most important clinical trial for 
demonstrating the beneficial effects of deprenyl in PD pa-
tients. From 1987 to 1988, a cohort was conformed of 800 
patients harboring early Parkinson’s disease. Subjects were 
randomized to receive deprenyl, tocopherol, combined 
treatments, or a placebo. The study showed that deprenyl 
(10mg/d) significantly delayed the onset of disability requir-
ing levodopa therapy [18]. A second independent randomiza-
tion was carried out in 1993 with 368 subjects, who, by that 
time, had required levodopa and who had consented to con-
tinue the study by adding deprenyl or placebo assigned under 
double-blind conditions to their treatment. The first devel-
opment of a levodopa complication, such as the wearing off 
phenomenon, dyskinesias, or on-off motor fluctuations, was 
the primary outcome measure. During the average 2-year 
follow-up, there were no differences between treatment 
groups with respect to the primary outcome measure, with-
drawal from the study, death or adverse events. Subjects 
under deprenyl developed more dyskinesias (34% vs.19% 
under placebo; p=0.006) and significantly less freezing of 
gait (16% vs. 29%; p=0.0003). Decline in motor perform-
ance was also less in subjects under deprenyl treatment. 
Levodopa-treated PD patients who had received deprenyl for 
up to 7 years, compared with patients who were changed to a 
placebo after about 5 years, experienced slower motor de-
cline and, additionally, were more likely to develop dyskine-
sias but less likely to develop freezing of gait [19]. An 
evaluation of the DATATOP cohort in subjects followed-up 
for two decades did not confirm the expected neuroprotec-
tion, since the interpretation of the results was confounded 
by a drug symptomatic effect [5]. The SIN-DEP-PAR (Si-
nemet-Deprenyl-Parlodel) study [20] used the change in mo-
tor score between initial visit and final visit after elimination 
of all study medications as the primary end point. However, 
here, too, there were concerns about confounding sympto-
matic effects, since several antiparkinsonian medications 
were shown to have a long duration response that could per-
sist for weeks and perhaps even months after withdrawal. 
Drugs that have already been approved in PD for their symp-
tomatic effects, such as dopamine agonists or propargy-
lamines, offer the best opportunity for establishing the neu-
roprotective feature of a drug, even if the observed benefits 
lie within their symptomatic properties. Currently, this will 
most likely require demonstrating that the drug provides 
benefit for PD patients using both imaging and clinical 
markers of disease progression [6, 17, 20]. As postural hy-
potension, a known side-effect of L-DOPA treatment, may 
be potentiated when L-DOPA is combined with selegiline, 
Table 1.  Potential Neuroprotective Agents Selected by the CINAPS Group as Good Candidates for Clinical Trials Phase II and III 
Compounds 
Prioritized and Presented in that Order by 
the CINAPS Group
Background, Further Studied Mechanisms and Present State  References 
[11]  
Caffeine  Epidemiological studies  
Adenosine A2A receptor antagonist 
[27] 
[30, 40] 
Coenzyme Q10 (ubidecarenone)  Antioxidant and mitochondrial enhancer. 
Improves both, safety and efficacy at higher doses 
[50] 
[51, 53,54] 
Creatine  Mitochondrial stabilizer and ATP synthesis enhancer.  
Good clinical results 
[49-50] 
[48] 
Estrogen  Epidemiological studies 
Transcription or signaling 
[37] 
[33-35] 
GM-1 ganglioside  Neurotrophic enhancer  
Low bioavailability when peripherally administered. 
[57-59] 
Minocycline  Anti-inflammatory and antiapoptotic actions through caspases 1 and 3 inhibition. 
Phase II clinical trial. 
[41-43, 46]  
[48] 
Nicotine  Epidemiological studies reveal decreased risk of PD in tobacco smokers.   
GPI 1485  Neuroimmunophilin ligand  [55-56] 
Rasagiline  MAO-B inhibitor (antioxidant/ antiapoptotic) 
TEMPO study, ADAGIO study 
[21-22] 
[24-26] 
Selegiline  MAO-B inhibitor (antioxidant/ antiapoptotic) 
DATATOP cohort 
[14]  
[18] 
Ropirinole  Dopamine D2/D3 receptor agonist that slows the rate of decline of functional markers  [68] 
Pramipexole  Dopamine D2/D3 receptor agonist. Enhances dopamine vesicular trafficking  [4, 66-67] 352    Current Neuropharmacology, 2011, Vol. 9, No. 2 Boll et al. 
other IMAO-B drugs lacking the sympathomimetic effects of 
selegiline seem to be indicated in subjects presenting this 
adverse event. 
2.1.2. Rasagiline 
  Lately, rasagiline (N-propargyl-1 (R)-aminoindan) has 
demonstrated to be a highly selective and irreversible potent 
inhibitor of MAO-B with properties similar to those de-
scribed for selegiline with the exception that, unlike se-
legiline, rasagiline is an aminoindan derivative with no am-
phetamine metabolites. Two important trials in PD patients, 
TEMPO (TVP-1012 in Early Monotherapy for Parkinson's 
Disease Outpatients) and LARGO (Lasting Effect in Adjunct 
Therapy With Rasagiline Given Once Daily), are successors 
of many preclinical studies that have demonstrated protective 
effects, in vitro as well as in vivo, against a wide range of 
neurotoxins [21]. Aminoindan is, by itself, neuroprotective 
in cultured PC-12 cells that, in absence of serum and nerve 
growth factor (NGF), die after an apoptotic process [22]. 
Rasagiline was shown to increase survival in a Cu/Zn SOD 
transgenic mouse model of ALS [23] and was the first with 
demonstrated efficacy, as initial monotherapy, in the large 
TEMPO study. Four hundred and four patients with early PD 
not requiring dopaminergic therapy were randomized to re-
ceive 1mg or 2mg once daily of oral rasagiline or placebo. 
Both dosages in this trial were effective in relation to pla-
cebo and the difference between 1 and 2 mg was not signifi-
cant [24]. In the extension phase of the TEMPO trial, pa-
tients initially under placebo also received rasagiline. As a 
result, the functional decline was significantly more pro-
nounced in patients whose treatment was deferred. Delayed-
start analysis of the TEMPO study suggests that rasagiline 
may slow the rate of progression of PD [25]. In fact, in the 
recent ADAGIO study, patients who received 72 weeks of 
treatment exhibited significant clinical differences with those 
receiving rasagiline for only the last 36 weeks [26]. The rate 
of progression in both groups was graphically represented by 
parallels, and the slopes never converged during the entire 
follow-up. The authors of this study maintain that the differ-
ence between groups illustrates the neuroprotection con-
ferred by early treatment in contrast to that provided by the 
delayed start. 
2.2. Caffeine 
  Epidemiological studies have firmly established the rela-
tionship between the consumption of caffeine and a low risk 
of PD [27]. Adenosine A2A receptor is a G protein–coupled 
type of ligand binding protein, abundant in basal ganglia and 
a target of caffeine. Adenosine A2A receptor antagonists and 
caffeine provide a broad spectrum of neuroprotection in dif-
ferent animal models of PD [28, 29] through the modulation 
of glutamate release and inflammation in the CNS [30]. 
KW6002, the adenosine A2A  receptor antagonist tested in 
many PD models, was found to enhance motor activity even 
in dopamine-depleted animals. Further named istradefylline, 
it was recently shown to improve motor function in patients 
with Parkinson´s disease [31]. 
2.3. Estrogen 
  Most animal studies support the ability of estrogen to 
function as a neuroprotective against neurotoxins that target 
the nigrostriatal dopaminergic system [32]. Glia-neuron 
crosstalk has been shown to play a cardinal role in directing 
neuroprotection  vs. neurodegeneration, in addition to the 
specific role exhibited by astroglia in modulating inflamma-
tion in estrogen neuroprotection, manifested as a variable 
response of astrocytes and microglia to MPTP injury accord-
ing to estrogenic status [33]. Other potentially protective 
properties are derived from the co-localization of estrogen 
receptors to cells that express BDNF and its receptor trkB,  
as well as the further regulation of the expression of this   
neurotrophin system [34]. Activation of membrane estrogen 
receptors also induce pro-survival kinases leading to   
CREB phosphorylation and NF B nuclear translocation,   
two transcription factors controlling the expression of anti-
apoptotic Bcl-2 proteins [35]. The relationship between the 
structure and the estrogenicity of flavonoid derivatives   
explains their protection on stressed dopaminergic neurons 
through the inhibition of microglial activation [36]. In   
clinical studies, estrogen therapy replacement in women has 
not only been associated with improved scores in the 
UPDRS (Unified Parkinson Disease Rating Scale) [37], but 
also with the reduction of peak-dose dyskinesias [38]. 
Meanwhile, oöphorectomy before the onset of menopause 
exhibited an increased risk of Parkinsonism, although this 
risk was generally similar in women using hormones and in 
those who had never used them [39]. However, estrogens 
were associated with a reduced risk of PD among women 
with low caffeine consumption, suggesting that caffeine, 
protective in men, reduces the risk of PD among women not 
using postmenopausal hormones, but increases the risk 
among hormone users [40]. 
2.4. Minocycline 
  Tetracyclines possess a wide range of antimicrobial ac-
tivity that works by exerting the inhibition of bacterial pro-
tein synthesis. Initially evaluated in ischemic tissues, mino-
cycline, a more lipophylic tetracycline derivative, has re-
markable neuroprotective properties. It has been demon-
strated that minocycline inhibits ischemia and induces up-
regulation of nitric oxide synthase, caspase 1 and reactive 
microgliosis [41-43]. Neuroprotection by minocycline has 
also been observed in HD and ALS transgenic mouse models 
[44, 45]. A primary mechanism has been proposed in which 
the release of cytochrome c is inhibited and the formation of 
apoptosome in the cytoplasm and downstream can cause a 
“contagious apoptosis”, since toxic factors generated by dy-
ing neurons can affect neighboring cells [46]. In the PD 
mouse model, minocycline attenuates MPTP-induced dopa-
minergic neurodegeneration and decreases MPTP-mediated 
nitrotyrosine formation and microglial activation. Mino-
cycline confers resistance to the MPTP toxin by preventing 
the production of deleterious microglial-derived mediators, 
such as proinflammatory cytokine IL-1, nitric oxide and 
ROS [47]. But, other than current experimental evidence for 
the potential use of minocycline in PD, there are still few 
clinical assays and no clinical evidence of its neuroprotective 
properties in PD patients. To this date, we can only mention 
one futility clinical trial of creatine and minocycline in early 
PD. Futility studies are phase II trials designed to eliminate 
drugs showing low potential, hence avoiding further large 
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the mean change in UPDRS in the placebo/tocopherol arm of 
the DATATOP study, neither minocycline nor creatine could 
be rejected as futile for further trials [48]. 
2.5. Creatine  
  This guanidine derived compound is converted to phos-
phocreatine, which serves to transfer phosphoryl groups in 
mitochondrial ATP synthesis. Creatine also reduces oxida-
tive stress through the stabilization of mitochondrial creatine 
kinase and the consequent opening of the mitochondrial tran-
sition pore that activates apoptosis [49]. A few experimental 
studies suggest a neuroprotective role of dietary intake of 
creatine in PD models. It is now considered for phase III by 
NINDS NET-PD Investigators, as the phase II futility study 
showed even better clinical results in the creatine group than 
in the minocycline one [48]. The study is currently recruiting 
participants for the creatine arm NET-PD LS-1. 
2.6. Coenzyme Q10  
  Several other agents have shown to be beneficial in PD 
animal models, such as, coenzyme Q10, ginkgo biloba, 
nicotinamide, and acetyl-L-carnitine [50]. Among them, co-
enzyme Q10, an essential cofactor of the electron transport 
chain as well as a potent antioxidant, has been prioritized 
[11]. A specific defect of Complex I (NADH-ubiquinone 
reductase ) in the mitochondrial respiratory chain has been 
described in the substantia nigra of patients with Parkinson's 
disease, similar to the effect of MPTP in those animal mod-
els that show specific destruction of the dopaminergic neu-
rons in the substantia nigra. Coenzyme Q10 is able to at-
tenuate this dopaminergic neuron induced loss through free 
radical scavenging and the specific regulation of the mito-
chondrial permeability transition pore [51, 52]. Although the 
serum levels of CoQ10 are normal in patients with Parkin-
son's disease, the administration of 300 mg, 600 mg and 
1200 mg CoQ10/d, respectively, showed a significant trend 
relating to dosages and mean change in UPDRS [53]. Safety 
and tolerance were found at the highest doses tested -2400 
and 3000 mg/d- when the plasma level plateau is reached 
[54].
  These effects were further tested in a phase II clinical 
trial together with another promising drug: GPI-1485. The 
results of this study indicate that both drugs should be con-
sidered for phase III studies. 
2.7. GPI-1485 
  This compound is a neuroimmunophilin ligand which 
acts by binding the intracellular receptor-protein, in a manner 
similar to some immunosuppressive drugs. Immunophilin 
ligands can be ingested orally and may promote nerve 
growth in a better fashion than neurotrophic factors [55] 
without clinical immunosuppressive activity.  
  The futility study was carried out with a threshold taken 
from the historical controls of the DATATOP study [18] 
with the indication that both drugs should be considered for 
phase III clinical trials. Nevertheless, using recent controls in 
both minocycline-creatine and coenzyme Q10- GPI-1485 
phase II studies, only creatine can still be considered a prom-
ising candidate for future studies, probably due to the 
marked low rate of change in UPDRS exhibited during a 
one-year interval in all groups [56]. 
2.8. GM1 Ganglioside 
  Since the early 1980s, numerous studies have docu-
mented the beneficial effects of GM1 ganglioside in different 
brain damage models. In addition to rescuing damaged do-
pamine neurons, when administered intra peritoneally, GM1 
was found to enhance the synthesis of dopamine in remain-
ing nigrostriatal neurons following MPTP exposure [57]. In 
PD patients, anti-GM1 ganglioside antibodies have been 
found, especially in those presenting a tremor-dominant form 
of the disease [58]. The last clinical trial of efficacy of GM1 
[59], despite manifesting safety and clinical improvement, 
did not have any continuity, probably due to the problem of 
bioavailability of the oral form and the requirement of intra-
venous or subcutaneous injections. 
2.9. Dopamine Agonists 
  Dopamine receptors, members of a super family of G 
protein-coupled receptors, play a crucial role in mediating 
the wide array of effects of dopamine in the CNS, especially 
in the limbic system and the motor control pathway. The five 
molecular human subtypes are divided into 2 subfamilies: 
D1-like receptors; D1 being the predominant form and D5,
and D2-like receptors; D2 being highly expressed, and D3 
and D4 rare. The division is based on their capability to 
stimulate adenylate-cyclase (D1-like) or to inhibit this en-
zyme (D2-like). D1 and D2 receptors, mainly found in the 
striatum and substantia nigra, are localized postsynaptically. 
D2 also acts presynaptically as an autoreceptor, modulating 
synthesis and release of dopamine, while D3, other autore-
ceptor, may control basal dopamine levels in the striatum 
without regulating dopamine transporters or tyrosine hy-
droxylase [60]. Currently used in clinical practice, DA ago-
nists include the ergot-derivatives bromocriptine, cabergo-
line, dihydroergocriptine (DHEC), lisuride and pergolide, as 
well as the non-ergot compounds apomorphine, piribedil, 
pramipexole, ropirinole and rotigotine. This distinction raises 
the question whether differences exist in their pharmacologi-
cal properties, therapeutic effects and safety. It is generally 
accepted that ergolines may cause retroperitoneal and pleu-
ropulmonar fibrosis (rarely) and valvulopathies in 30% of 
patients under treatment with pergolide. Probably, other er-
got-derivative DA agonists such as cabergoline may cause 
the same severe adverse events [61]. As cardiovascular risk 
factors could represent confounders or cofactors, performing 
an echocardiography before initiation of treatment with a 
dopamine agonist is recommended [62]. The exact pathway 
leading to valvulopathy is unknown, although agonism of 5-
HT(2B) receptors in the heart has been implicated as a me-
diator in the process. Other ergolinic dopamine agonists, 
such as lisuride, and non-ergot dopamine agonists with no 5-
HT(2B) agonistic activity, may not induce fibrotic changes 
in heart valves. Given the clinical consequences of the ad-
verse reactions, affinity for 5-HT(2B) receptors must be rou-
tinely tested in future drugs [63]. One interesting finding 354    Current Neuropharmacology, 2011, Vol. 9, No. 2 Boll et al. 
drawn from clinical trails is that four chemically different 
DA agonists: ropirinole, pramipexole, cabergoline and per-
golide delay the necessity of levodopa treatment in PD pa-
tients and also decrease the occurrence of prolonged L-
DOPA treatment complications [64]. The treatment of early 
Parkinson's disease with bromocriptine may also be benefi-
cial in delaying motor complications and dyskinesias with 
comparable effects on impairment and disability in those 
patients that tolerate the drug bromocriptine versus levodopa 
in early Parkinson's disease [65]. 
2.9.1. Pramipexole 
  Pramipexole is a dopamine D2/D3 receptor agonist used 
to treat Parkinson's disease. Both human and animal studies 
suggest that pramipexole may exhibit neuroprotective prop-
erties involving dopamine neurons. However, the mecha-
nisms underlying its neuroprotective effects remain uncer-
tain. The results of Pan et al. [8] reveal a novel cellular ac-
tion of this agent. Specifically, pramipexole rapidly increases 
vesicular dopamine uptake in synaptic vesicles prepared 
from striata of treated rats. This effect presents the following 
characteristics: 1) it is associated with a redistribution of 
vesicular monoamine transporter-2 (VMAT-2) immunoreac-
tivity within nerve terminals, and 2) it is prevented by pre-
treatment with the dopamine D2 receptor antagonist, eticlo-
pride. The implication of these findings is relevant to the 
treatment of several neurodegenerative disorders involving 
the dopaminergic system [4, 66, 67].
2.9.2. Ropirinole  
  Another D2/D3 dopamine agonist available in some 
countries, ropirinole, besides providing preclinical evidence 
of neuroprotective properties, has also shown a slower rate 
of decline of functional markers in 18 F-DOPA PET-scans, 
compared to levodopa [68]. No difference in the progression 
of motor impairment has been found between new agonists 
and levodopa [69]. 
  Possible side effects of all DA agonists are nausea, vom-
iting, hypotension, leg-edema, dizziness and bradycardia, 
due to autonomic peripheral stimulation. Co-administration 
of a peripheral DA receptor blocker, domperidone, can coun-
teract these symptoms. Central side effects -such as somno-
lence [70] and hallucinations- are less frequent with carbi-
dopa/levodopa as initial treatment but the advantages of new 
agonists -such as pramipexole and ropirinole- are possible 
neuroprotection and lower frequency of dyskinesias and mo-
tor fluctuations [71]. DA agonists as adjuncts to levodopa 
generally reduce motor fluctuations by increasing “ON” time 
and reducing “OFF” time [72]. Low acting agonists -
cabergoline, piribedil, DHEC and pergolide- do not generally 
induce dyskinesias in primate models [73]. L-DOPA induced 
dyskinesias are also improved by high doses or continuous 
subcutaneous infusion of apomorphine or lisuride, with re-
sults similar to those of levodopa intravenous and enteral 
(duodenal/jejunal) infusion [74]. A transdermal patch formu-
lation of rotigotine, the non-ergolinic D3, D2, D1 receptor 
agonist, is now being proposed for use as monotherapy in the 
treatment of early-stage Parkinson's disease as an adjunct to 
levodopa [75]. 
3. NEW PROMISING DRUGS FOR NEUROPROTEC-
TION IN PD-PATIENTS 
3.1. Istradefylline 
 This  adenosine  A2A  receptor antagonist (like caffeine) 
exerts motor effects at a daily dose of 40 mg now reported in 
a clinical trial [31]. Other good prospects for PD therapeutics 
are presented in Table 2.
3.2. Zonisamide  
  This drug, 1,2-benzisoxazole-3-methanesulfonamide, is 
indicated as an adjunct therapy for partial seizure disorders. 
Zonisamide acts by blocking voltage gated sodium and cal-
cium channels. It modulates central dopaminergic, GABAer-
gic and serotonergic pathways, and inhibits carbonic anhy-
drase and monoamine oxidase B. Therefore, it is potentially 
efficient in an array of other neurological disorders including 
migraine and other headache syndromes, neuropathic pain, 
Parkinson's disease, essential tremor and stroke [76]. A mul-
ticenter, randomized, double-blind, placebo-controlled study 
was recently conducted in Japanese PD patients, showing 
significant improvement in the motor subscale of the 
UPDRS with 25 and 50 mg /d as adjunctive treatment to 
levodopa therapy [77]. Effects of zonisamide against DA 
quinone formation could be protective since DA quinones 
conjugate with several key PD pathogenic molecules (e.g., 
tyrosine hydroxylase, alpha-synuclein and parkin) to form 
protein-bound quinone (quinoprotein) and consequently in-
hibit their functions [78]. 
3.3. Safinamide 
  A new agent, safinamide, a monoamine oxidase-B and 
glutamate release inhibitor, is now in phase III development. 
Although not yet approved, safinamide may offer the added 
advantage of dopamine reuptake inhibition. Early reports 
confirm the potential efficacy of this unique molecule in PD, 
although studies on its effects on cognition and neuroprotec-
tion are needed [79, 80]. 
3.4. Resveratrol 
  Sirtuins, a family of conserved proteins with deacetylase 
and ADP-ribosyltransferase activities, are other good pros-
pects in PD therapeutics. The most widely investigated and 
best known sirtuin is SIRT1. The human gene corresponds to 
yeast sir-2. Enhancement of SIRT 1 and reduction of SIRT2 
expression delay the toxic effect induced by -synuclein, the 
protein that forms insoluble aggregates in dying dopamine 
neurons [81]. SIRT1, which can be activated by the natural 
phytocompound resveratrol, plays a role in several physiol-
ogic conditions ranging from gene silencing, control of the 
cell cycle, apoptosis and energy homeostasis. A famous 
study of the role of sirtuins on the extension of life-span in 
caloric restriction models [82] was rapidly followed by the 
commercialization of several presentations of reverastrol 
capsules, before having clearly stated the purity percentage 
which indicates the contribution of trans-R (the active form) 
in relation to total product weight. Those presentations are 
promoted in many dietary and well-being management pro-
grams. In the field of neurodegeneration, resveratrol has Medical Management of Parkinson’s Disease  Current Neuropharmacology, 2011, Vol. 9, No. 2    355
proved to be beneficial in in vitro and in vivo models of Alz-
heimer's disease (AD) by reducing amyloid-beta protein ac-
cumulation [83]. So far, no work on PD has been published, 
but recent literature strengthens the perception that diverse 
molecular signaling pathways are participating in the neuro-
protective activity of many phytocompounds, and a new trial 
with green tea polyphenols is now recruiting PD patients.  
4. OLD DRUGS WITH NEW PROPERTIES 
4.1. Amantadine 
  In 1968, a 58-year-old female patient reported that her 
Parkinson’s symptoms had decreased while she was taking 
amantadine to prevent the flu. The first trials with this drug 
in PD showed a peak effect during the first week with one 
half of the patients showing improvement [84]. Moreover, 
the beneficial effects were definite but usually brief. After 
three decades of empiric use of amantadine in PD, the drug 
was finally characterized as a noncompetitive NMDA (N-
methyl D-aspartate) receptor antagonist [85, 86]. When acti-
vated, the NMDA receptor, a specific type of ionotropic 
glutamate receptor, plays a key role in a wide range of 
physiologic and pathologic processes, such as calcium-
mediated excitotoxicity. A 2001 Cochrane review pointed 
out in its conclusions that the considerable amount of evi-
dence supporting the effectiveness of amantadine was ac-
crued from non-controlled trials, often in patients with Park-
inson’s condition other than idiopathic PD and that a rigor-
ous analysis of the six controlled trials revealed insufficient 
evidence of its efficacy in the disease [87]. Since then, like 
its congener memantine, amantadine showed improvement 
of both levodopa induced dyskinesias and PD subcortical 
dementia [88]. Additionally, an amantadine treatment and its 
duration were significantly correlated with a late onset of 
dementia as well as attenuation of its severity in PD patients 
[88]. 
4.2. Valproic Acid  
  Valproic acid (VPA), an established antiepileptic and 
mood-stabilizer drug, has recently emerged as a promising 
neuroprotective agent. This aliphatic acid compound repre-
sents with the orphan drug phenylbutyrate a class of histone 
Table 2.  Other Agents Currently Used in Clinical Practice, or Reaching Clinical Phases of their Development, with a Neuroprotective 
Focus 
Compounds Mechanisms  References 
Amantadine 
Memantine 
Both, uncompetitive NMDA
* antagonists and, therefore, antiexcitotoxic compounds. 
Amantadine is indicated in PD tremor and dyskinesias, whereas memantine is used 
in degenerative dementiae.  
Studies in PD neuroprotection are pending 
[85-86] 
Lamotrigine 
Levetiracetam 
Riluzole 
AED
* Decreased glutamate mediated excitotoxicity. 
Riluzole that increases life span in ALS patients did not have a significant effect on 
survival or rate of functional deterioration in Parkinson plus syndromes.
[23] 
[107] 
Talampanel  Antagonism of excitatory amino acid receptors (AMPA
*). [104] 
Istradefylline  Adenosine A2A receptor antagonist.  [28, 31] 
Resveratrol 
Green tea polyphenols 
SIRT 1 histone deacetylase enhancer. 
diverse molecular signaling pathways participating in the neuroprotective activity 
[81-82] 
Approved clinical trial now 
recruiting PD patients 
Safinamide  MAO-B
* inhibitor that also acts on glutamate pathway  [79-80] 
Ebselen  
Thiol containing antioxidants 
Mimics glutathione peroxidase activity. 
Avoids glutathione depletion within CNS. 
Clinical trials in stroke 
CEP-1347  Antiapoptotic through mixed-lineage kinases inhibition 
Failed in PD 
[104-105] 
GDNF  Neurotrophic factor. Methods for the delivery of GDNF
* into basal ganglia  
are discussed in the referenced review  
[104] 
GAD gene delivery  The first illustration of gene therapy reaching clinical phase I by the mean of a viral 
vector implanted in the STN
*
[104-105] 
Zonisamide  Inhibition of DA-induced quinone toxicity. Increased levels of glutathione  
and manganese superoxide dismutase expression. 
Moderate inhibition of MAO-B activity. Inhibition of voltage-dependent  
sodium and T-type calcium channels. 
[78] 
*NMDA= N-methyl D-aspartate; AMPA= -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AED= antiepileptic drugs; MAO-B= Type B Monoamine Oxidase; GAD= Glu-
tamate Decarboxylase; STN= Subthalamic Nucleus; GDNF= Glial Cell Line-Derived Neurotrophic Factor.356    Current Neuropharmacology, 2011, Vol. 9, No. 2 Boll et al. 
deacetylase (HDAC) inhibitors. Moreover, VPA has been 
shown to mediate neuronal protection by activating signal 
transduction pathways and inhibiting proapoptotic factors. In 
a cerebral hemorrhage model, VPA inhibited caspase activi-
ties. In addition, inflammatory cell infiltration was associated 
with enhanced histone H3 acetylation, expression of   
extracellular signal regulated kinases, CREB, heat shock 
protein HSP70, Bcl-2 and Bcl-xl, whereas the expression of 
Fas-L (a proapoptotic factor), matrix metalloproteinase-9 and 
interleukin 6 (IL-6; marker of inflammation) were down-
regulated [89]. In an animal model of PD, in which degen-
eration of nigro-striatal dopaminergic neurons is obtained 
through sub-chronic administration of rotenone, a mitochon-
drial toxin, a treatment with VPA counteracted the death of 
nigral neurons and the 50% drop of striatal dopamine levels 
as well as the alpha-synuclein alterations caused by rotenone 
[90]. No results in PD patients are still available.  
4.3. Lithium Carbonate 
  Lithium has been used for six decades to treat mania, the 
up phase of bipolar disorder. Lithium ions interfere with the 
sodium pump that relays and amplifies messages carried to 
the cells of the brain and act by inhibiting protein kinase C 
(PKC) activity. Daily doses of lithium have been found to 
delay progression of ALS in a recent clinical trial performed 
in a small group of patients [91]. In the same report, an 
experiment in SOD1 transgenic mice reported decreased 
ubiquitin, SOD1 and alpha-synuclein aggregation in Li-
treated animals. Also, mitochondrial vacuolization and 
astrocytic proliferation were decreased under lithium 
treatment. Finally, the most important finding reported in 
this experiment was the marked increase in autophagy vacu-
oles in motoneurones from treated animals. Autophagy is a 
critical pathway that regulates the clearance of aggregated 
proteins among diverse intracellular pathogens. Lithium and 
valproic acid, by acting on the mTOR-independent pathway, 
enhance autophagy and are therefore protective in different 
neurodegenerative models [92]. To this day, Li is still not 
indicated for the treatment of PD, but, interestingly, a robust 
synergistic protective effect of Li and VPA used in combina-
tion has recently been described in an ALS mouse model 
[93]. Glutamate mediated excitotoxicity as well as glycogen 
synthase kinase 3 (GSK-3) activity were significantly   
decreased by this combined treatment.
4.4. Copper Sulfate 
  Copper is an essential trace element present in serum and 
bound to ceruloplasmin (93% of total serum copper) or al-
bumin (7% of total serum copper). Since copper ions adopt 
distinct redox states, they play an important role in cell 
physiology as cofactors in the redox chemistry of enzymes 
involved in a variety of biological activities, such as complex 
IV of mitochondrial respiratory chain (cytochrome c oxi-
dase) and other powerful free radical scavengers (metal-
lothionein, superoxide dismutase and ceruloplasmin, among 
others). The neurodegenerative phenotypes of Menkes’ and 
Wilson’s diseases underscore not only the essential nature of 
this metal in nervous system development, but also the con-
sequences of the unbalanced neuronal copper homeostasis. 
Moreover, inherited deficiency of ceruloplasmin is associ-
ated with progressive retinal and basal ganglia neurodegen-
eration [94]. Recent studies have also indicated the involve-
ment of copper in the pathogenesis of Alzheimer’s disease, 
prion-mediated encephalopathy, amyotrophic lateral sclero-
sis and PD. Our results showed that increased levels of free 
copper in the CSF seem to be a good marker of several neu-
rodegenerative diseases, but mainly PD [95]. These findings 
have been related to the reduced ferroxidase activity of brain 
ceruloplasmin and increased iron deposition in SNc. Copper 
acts as a prosthetic group of several copper-dependent anti-
oxidant enzymes. When administered in a mouse model of 
PD as a pretreatment, CuSO4 showed its neuroprotective effect 
against the administration of 1-methyl-4-phenylpiridinium 
(MPP+), the toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), by blocking lipid peroxidation. 
The dose and time dependent protection observed have been 
associated with the safeguarding of striatal DA levels [96]. 
In the same model, a specific and significant increase in 
manganese superoxide dismutase activity was found under 
copper treatment [97]. Copper pretreatment also prevented 
tyrosine hydroxylase inactivation by blocking protein nitra-
tion in rats [98] and mice [99]. These results were accompa-
nied by a significant reduction in enzymatic activity of the 
constitutive nitric oxide synthase (cNOS), whereas protein 
levels of the three isoforms of NOS remained unchanged 
[98]. Mice motor disturbances (rigidity) induced by the 
MPP+ model and associated with dopamine depletion were 
also blocked by CuSO4 [99]. Nowadays, our group is per-
forming a clinical trial in PD patients under a 10 mg copper 
sulfate supplement b.i.d. controlled with placebo. 
5. CONCLUSIONS 
  In conclusion, let us first refer to levodopa therapy. This 
is the most powerful replacement treatment and, therefore, 
the gold standard in PD therapeutics, but the following di-
lemma remains unsolved: “Is it toxic or neuroprotective?” In 
our experience, we have elements that argue both in favor 
and against the toxicity of levodopa. For example, the en-
hanced production of hydrogen peroxide and the subsequent 
deleterious hydroxyl (
.OH) free radical, via the Fenton reac-
tion, in presence of transition metals, is a consequence of the 
excessive catabolism of this monoamine. On the other hand, 
under this treatment, the activity of two protective enzymes 
Cu/Zn SOD and Cp/ferroxidase are significantly increased 
[95]. Also, levodopa is responsible for the remarkable in-
crease in survival and quality of life in PD subjects. The 
principal objective of the ELLDOPA study was to analyze 
rates of progression of PD by taking the mean of the changes 
in the UPDRS in patients under different doses of levodopa 
or placebo [100]. The clinical benefit under levodopa at 
week 42 was marked and dose-dependent [101]. An external 
analysis also showed that a dose-related increased rate of 
progression in Parkinson's disease, obscured by symptomatic 
benefit, is very unlikely [102]. Nevertheless, beta-CIT up-
take in the striatum of those patients was proportionally de-
creased with the dose of levodopa [103]. The doubt is still 
pending when faced with the possible interpretations of these 
results, since beta-CIT uptake could be decreased by neu-
ronal loss or by the proper pharmacological effect of 
levodopa. But the actual tendency in neurological practice 
focuses on the conservation of the clinical benefits of 
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trying to decrease the cumulative dose and the consequent 
motor complications, and by adding a personalized combina-
tion of a dopamine agonist and other potentially neuroprotec-
tive medication. The recent ADAGIO study, through the 
delayed start design testing putative neuroprotective therapy 
and avoiding symptomatic confound, is solid evidence for an 
earliest use of rasagiline. In the horizon of PD treatment, 
appear large amounts of agents already showing excellent 
results in preclinical and phase I studies [104, 105]. A sam-
ple of this is shown in Table 2. Some of these compounds 
are destined to fail in clinical phases [106, 107]. New strate-
gies to assay neuroprotective properties are a burning need in 
human subjects. In addition, actual neuroimage markers, like 
other in vivo markers, require to be developed to obtain solid 
criteria for the conceptual framework of cell protection in 
clinical trials. 
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